PI-1840

PI-1840 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α[1][2].

Product Specifications

CAS Number

[1401223-22-0]

UNSPSC

12352005

Hazard Statement

H317-H319

Target

Apoptosis; Autophagy; Bcl-2 Family; Caspase; NF-κB; PARP; Proteasome

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PI-1840.html

Purity

98.78

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(N(C(C)C)CC1=NC(C2=CC=CN=C2)=NO1)COC3=CC=C(CCC)C=C3

Molecular Formula

C22H26N4O3

Molecular Weight

394.47

Precautions

P261-P264-P272-P280-P302+P352-P305+P351+P338-P362+P364-P501

References & Citations

[1]Kazi A, et, al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014 Apr 25;289 (17) :11906-11915.|[2]Chen Y, et, al. Non covalent proteasome inhibitor PI 1840 induces apoptosis and autophagy in osteosarcoma cells. Oncol Rep. 2019 May;41 (5) :2803-2817.